O 6 -Methylguanine-DNA methyltransferase (MGMT), an enzyme that repairs adducts at O 6 of guanine in DNA, is a major determinant of susceptibility to simple methylating carcinogens or of tumor response to anticancer chloroethylating drugs. To investigate the mechanisms underlying cellular expression of this DNA repair enzyme, we focused on the role of a 59-bp enhancer of the human MGMT gene in the regulation of its expression. By using chloramphenicol acetyltransferase reporter assays, we found that the enhancer activity, which was present in both MGMTexpressing (Mer ؉ ) and -deficient (Mer ؊ ) cells, correlated with the endogenous MGMT activity in Mer ؉ cell lines. Band-shift assays and deletion analysis of the 59-bp sequence defined a minimal 9-mer cis element (5-CTGGGTCGC-3) for specific trans factor binding. The DNA repair protein O 6 -methylguanine-DNA methyltransferase (MGMT) repairs cytotoxic and mutagenic alkylation damage produced by anticancer drugs, such as 1,3-bis(2-chloroethyl)-1-nitrosourea, and by carcinogenic agents, such as N-methyl-N-nitrosourea or 1-methyl-3-nitro-1-nitrosoguanidine (1). MGMT acts in a stoichiometric manner, transferring alkyl groups from the O 6 position of guanine in DNA to a cysteine residue in its own sequence. This transfer inactivates MGMT and is irreversible; hence, a cell's ability to withstand such damage is directly related to the number of MGMT molecules it contains and to the rate of de novo MGMT synthesis. The importance of MGMT levels in determining responses both to chemotherapy with chloroethylnitrosoureas and to carcinogenesis by methylating agents has been clearly demonstrated (2-4); however, how these levels are regulated in human cells is not yet understood. In rodents, MGMT can be induced, albeit at modest levels; yet, there is no clear evidence for such inducibility in human cells (5). Whereas all normal human tissues and cultured cell lines (Mer ϩ phenotype) constitutively express MGMT, a subset of tumor cell lines appears to be totally MGMT-deficient (Mer Ϫ phenotype) (6, 7). MGMT levels vary according to tissue or cell type (8), which indicates that mechanisms must exist to strictly regulate these levels in Mer ϩ cells and to suppress MGMT in Mer Ϫ cells. The MGMT gene is present in Mer Ϫ cells with no gross rearrangements or deletions; however, both the protein and mRNA are essentially undetectable (9-11). In Mer ϩ cells, MGMT mRNA levels generally correlate well with protein levels (9-11). Measurements of MGMT transcription rate by nuclear run-on assay have not proven feasible, because the mRNA is relatively stable and the transcription rate is correspondingly low. The mRNA stability is no greater in cells with high levels at MGMT than it is in cells with lower MGMT levels. This finding suggests that regulation occurs at the level of transcription (12).
The DNA repair protein O 6 -methylguanine-DNA methyltransferase (MGMT) repairs cytotoxic and mutagenic alkylation damage produced by anticancer drugs, such as 1,3-bis(2-chloroethyl)-1-nitrosourea, and by carcinogenic agents, such as N-methyl-N-nitrosourea or 1-methyl-3-nitro-1-nitrosoguanidine (1) . MGMT acts in a stoichiometric manner, transferring alkyl groups from the O 6 position of guanine in DNA to a cysteine residue in its own sequence. This transfer inactivates MGMT and is irreversible; hence, a cell's ability to withstand such damage is directly related to the number of MGMT molecules it contains and to the rate of de novo MGMT synthesis. The importance of MGMT levels in determining responses both to chemotherapy with chloroethylnitrosoureas and to carcinogenesis by methylating agents has been clearly demonstrated (2) (3) (4) ; however, how these levels are regulated in human cells is not yet understood. In rodents, MGMT can be induced, albeit at modest levels; yet, there is no clear evidence for such inducibility in human cells (5) . Whereas all normal human tissues and cultured cell lines (Mer ϩ phenotype) constitutively express MGMT, a subset of tumor cell lines appears to be totally MGMT-deficient (Mer Ϫ phenotype) (6, 7) . MGMT levels vary according to tissue or cell type (8) , which indicates that mechanisms must exist to strictly regulate these levels in Mer ϩ cells and to suppress MGMT in Mer Ϫ cells. The MGMT gene is present in Mer Ϫ cells with no gross rearrangements or deletions; however, both the protein and mRNA are essentially undetectable (9) (10) (11) . In Mer ϩ cells, MGMT mRNA levels generally correlate well with protein levels (9) (10) (11) . Measurements of MGMT transcription rate by nuclear run-on assay have not proven feasible, because the mRNA is relatively stable and the transcription rate is correspondingly low. The mRNA stability is no greater in cells with high levels at MGMT than it is in cells with lower MGMT levels. This finding suggests that regulation occurs at the level of transcription (12) . Accordingly, to better understand the transcriptional regulation of MGMT, we identified and characterized a 1.2-kb maximal promoter sequence that contains the minimal promoter (88 bp) and a 59-bp enhancer (13, 14) . In chloramphenicol acetyltransferase (CAT) reporter gene assays, the 1.2-kb fragment showed promoter activity in several Mer Ϫ cells as well as in Mer ϩ cell lines, leading us to conclude that the deficient cells do not lack any essential transactivating factors (15) . Herein, we further these studies by focusing on the possible role of the MGMT enhancer in the regulation of constitutive MGMT expression in Mer ϩ cells. We show, with reporter gene assays, that the enhancer activity correlates with MGMT levels in a panel of Mer ϩ cell lines, and we define the minimum protein-binding sequence within the enhancer element. The MGMT enhancer-binding protein (MEBP) was present in both Mer ϩ and Mer Ϫ cells; however, it was excluded from the nucleus of Mer Ϫ cells. We discuss the implications of these data on the role of MEBP in MGMT regulation. Preparation of Nuclear and Cytoplasmic Extracts. Nuclear extracts were prepared essentially as described by Zerivitz and Akusjarvi (16) . Logarithmically growing cells were harvested and washed twice with phosphate-buffered saline (PBS) at room temperature. After centrifugation at 1000 ϫ g for 5 min at room temperature, 10 8 cells were resuspended in 1 ml of buffer A [0.25 M sucrose͞20 mM Hepes, pH 7.9͞10 mM KCl͞1.5 mM MgCl 2 ͞ 0.5 mM dithiothreitol (DTT)͞0.5 mM spermidine͞0.15 mM spermine]. After incubation in buffer A for 5 min at room temperature, 40 l of lysolecithin at 10 mg͞ml was added, and the cells were gently swirled for 90 sec, before 2 vol of ice-cold buffer B (buffer A͞3% bovine serum albumin) was added; all subsequent procedures were at 4ЊC. Nuclei were pelleted by centrifugation at 1000 ϫ g for 30 sec and the pellets were washed twice in 2 ml of buffer B. After removing the supernatant, 2 ml per 10 9 cells of buffer C (20 mM Hepes, pH 7.9͞25% glycerol͞0.42 M NaCl͞1.5 mM MgCl 2 ͞0.2 mM EDTA͞0.5 mM DTT͞0.5 mM phenylmethylsulfonyl fluoride) was added, and the nuclei were disrupted by passing the mixture through a 23-gauge needle 15-20 times. After gentle stirring on ice for 30 min, the mixture was centrifuged at 25,000 ϫ g for 30 min. The supernatant was then removed and dialyzed overnight against buffer D (20 mM Hepes, pH 7.9͞20% glycerol͞0.1 M KCl͞0.2 mM EDTA͞0.5 mM DTT͞ 0.5 mM phenylmethylsulfonyl fluoride). After further centrifugation at 25,000 ϫ g for 20 min, the supernatant was divided into aliquots, stored in vials, quick-frozen, and stored at Ϫ70ЊC. Cytoplasmic extracts were prepared as described by Malter (17) . Proliferating cells were removed from culture flasks, pelleted by centrifugation, and washed twice in PBS. Cell pellets were transferred to Eppendorf tubes, resuspended in 5 vol of 25 mM Tris⅐HCl, pH 7.8͞0.5 mM EDTA, and lysed by four cycles of freezing and thawing as described (17) . Lysates were then centrifuged at 15,000 ϫ g at 4ЊC for 10 min, and the supernatants were removed, quick-frozen, and stored at Ϫ70ЊC. The protein concentration of each nuclear and cytosolic extract was determined by using the Bio-Rad protein assay kit.
MATERIALS AND METHODS

Cell
DNA Oligonucleotides. Complimentary strands of DNA oligonucleotides, containing the appropriate DNA sequence and desired 5Ј or 3Ј deletions were synthesized, in vitro by the Center for BioTechnology (St. Jude Hospital, Memphis, TN), suspended in water at 15 g͞ml, and stored at Ϫ20ЊC.
After annealing complimentary strands and confirming their size by electrophoresis, 15 ng of DNA oligonucleotide was 5Ј-end-labeled by the addition of 100 Ci of [␥-32 P]ATP (Amersham; 1 Ci ϭ 37 GBq), 10 units of T 4 polynucleotide kinase (New England BioLabs), and kinase buffer (70 mM Tris⅐HCl, pH 7.6͞10 mM MgCl 2 ͞5 mM DTT). After incubation at 37ЊC for 1 h, the mixture was heated at 65ЊC for 5 min to inactivate the enzyme. 32 P-labeled DNA oligonucleotides were purified with a Bio-Spin chromatography column, and the radioactivity was determined by scintillation spectrophotometry.
Band-Shift Assay. Band-shift assays were performed by incubating, at 16ЊC for 1 h, 30 g of nuclear or cytoplasmic protein, with 2 ϫ 10 5 cpm of 32 P-labeled DNA oligonucleotides (2.5 nM) in DNA-protein binding buffer (15 mM KCl͞5 mM MgCl 2 ͞0.25 mM EDTA͞0.25 mM DTT͞12 mM Hepes, pH 7.9)͞10% glycerol͞heparin (5 mg͞ml)͞yeast tRNA (200 ng͞ l), in a total volume of 10 l (18). Binding was competed by preincubating the protein extract for 30 min with various amounts of unlabeled competitive oligonucleotides and then adding the radiolabeled enhancer DNA oligonucleotides. Competitor to probe ratios were all based on molar concentration of oligonucleotide. Protein-DNA complexes were electrophoretically separated in 6% native polyacrylamide gels with running buffer (44.5 mM Tris borate, pH 8.0͞1 mM EDTA) in a Bio-Rad Protean II gel apparatus. After electrophoresis at 250 V for 1 h, gels were dried and exposed to Kodak X-Omat AR film at Ϫ70ЊC.
Southwestern Blot Analysis. Nuclear protein was denatured, by boiling for 4 min, and loaded on to an SDS 12% polyacrylamide gel (19) . After electrophoresis, the separated protein bands were transferred to poly(vinylidene difluoride) membranes (Immobilon-P, Millipore) by the method of Towbin et al. (20) . The membrane was blocked for 30 min at room temperature with 5% nonfat dry milk in the DNA-protein binding buffer, before it was hybridized for 1 h at room temperature with the 32 P-labeled 16-bp DNA oligonucleotide at 1 ϫ 10 6 cpm͞ml. The membrane was then given three 10-min washes at room temperature with the binding buffer containing 0.1% Nonidet P-40, air-dried, and exposed to Kodak X-Omat AR film.
Western Blot Analysis. Cell extracts were prepared essentially as described by von Wronski et al. (11) . Proteins (40 g) were separated by electrophoresis in 12% polyacrylamide gels in a Bio-Rad Mini Protean II system. Proteins were electroblotted to poly(vinylidene difluoride) membranes and probed with anti-MGMT monoclonal antibody MT5.1 and an anti-␤-tubulin monoclonal antibody (ICN), as described (11) .
CAT Reporter Gene Assay. MGMT 5Ј flanking gene sequences were inserted into vector pOCAT1 (a gift from D. D. Moore, Harvard Medical School) (21) . This plasmid contains the bacterial CAT gene and polyadenylylation signals derived from herpes simplex virus and simian virus 40 (SV40) virus genes. The previously defined 88-bp minimum MGMT promoter sequence (14) was excised from a 1.2-kb maximal promoter fragment BamHI-SstI located at positions Ϫ954 to ϩ203 with respect to the transcription start site within the MGMT genomic sequence (14) . pCAT͞MP ( Fig. 1, construct  I ) was generated by cloning the 88-bp minimal promoter sequence into pOCAT1 at the XbaI site such that the sensestrand CAT sequence located downstream of the promoter could be transcribed (14) . We then created a series of constructs based on pCAT͞MP. pCAT͞MP-E59 and pCAT͞MP-FIG. 1. Schematic diagrams of MGMT-CAT cDNA constructs. Construct I (pCAT͞MP) contains the full-length CAT cDNA and the 88-bp MGMT minimum promoter sequence subcloned into an XbaI site upstream of the HincII site in the polylinker of pOCAT1. Constructs II (pCAT͞MP-E59), III (pCAT͞MP-E59inv), IV (pCAT͞ MP-E16), and V (pCAT͞MP-E16.16) were generated by insertion, respectively, of the MGMT 59-bp enhancer sequence, the inverse 59-bp sequence, 16-bp enhancer sequence, or tandem copies of the 16-bp sequence into the HincII site. E16 (Fig. 1, constructs II and IV) were made by inserting the 59-bp or a synthetic 16-bp MGMT enhancer fragment, respectively (see Fig. 3A ), into a polylinker HincII site. pCAT͞MP-E59 inv (Fig. 1, construct III) was prepared by subcloning the 59-bp fragment into the HincII site in the inverse orientation; pCAT͞MP-E16.16 ( Fig. 1, construct V) was produced by inserting tandem copies of the 16-bp enhancer sequence into the polylinker site. Correct orientation and integrity of the inserted fragments were established by DNA sequencing.
The constructs were electroporated into cells by using a Bio-Rad Gene Pulser apparatus at 960 F and 220-240 V (22) . pSV-␤-Gal (5 g) (Promega), a plasmid that expresses ␤-galactosidase under the control of the SV40 promoter, was cotransfected with each CAT-MGMT hybrid construct to control for transfection efficiency.
Enzyme Assays. CAT and ␤-galactosidase activities were measured in crude cell extracts 48 h after transfection. CAT activity was measured by a two-phase liquid scintillation counting assay using [ 3 H]acetylcoenzyme A (Amersham) as a substrate (23) . ␤-Galactosidase activity was assessed spectrophotometrically with chlorophenol red ␤-D-galactopyranoside (Boehringer-Mannheim) as the substrate (24) . CAT activity was calculated as cpm of [ 3 H]acetylchloramphenicol per h per mg of protein, divided by the ␤-galactosidase activity (A 570 per h per mg) to correct for differences in transfection efficiency. MGMT activity was measured as described (25) using a DNA substrate treated with [ 3 H]methylnitrosourea (22 Ci͞mmol) . Western blot analysis of MGMT was performed by electrophoresis of cell extracts (50 g) on a SDS͞12% polyacrylamide gel (by using a Bio-Rad MiniProtean II system), followed by protein electroblotting to poly(vinylidene difluoride) membranes (Immobilon P; Millipore, Bedford, MA). Membranes were cut horizontally into two pieces. The section containing the higher molecular weight protein was probed with an anti-␤-tubulin monoclonal antibody (Sigma), and the lower section was probed with the anti-MGMT monoclonal antibody MT3.1 (26) . Gold-labeled secondary antibody was silverenhanced with Auroprobe and IntenSE reagents (Amersham), according to the manufacturer's instructions.
RESULTS
MGMT Enhancer-Mediated Up-Regulation of CAT Expression Correlates with Endogenous MGMT Levels. Previous experiments (14) in this laboratory identified a 59-bp DNA enhancer sequence located at the first exon-intron boundary of the human MGMT gene. We measured the CAT activity due to the enhancer in pCAT͞MP-E59 (Fig. 1, construct II) relative to that of pCAT͞MP containing only the minimal promoter (Fig. 1, construct I ) and the MGMT activity in various human Mer ϩ cell lines. As demonstrated in Fig. 2 , CAT expression was significantly higher in those cells (e.g., CEM) that contained high levels of MGMT compared with those cells (e.g., WI38) that had relatively low MGMT activity (R ϭ 0.77; P Ͻ 0.000004). These observations may reflect differences in MGMT enhancer activity among the different cell lines.
Minimal Enhancer Cis Element Required for Interaction with MEBP. To define the cis element(s) within this enhancer sequence, the full-length fragment and its three related large subfragments (Fig. 3A) were synthesized, 5Ј-radiolabeled, and incubated with nuclear extract from CEM cells (a Mer ϩ cell line), before analysis of DNA-protein complexes in an electrophoretic band-shift assay. We found that the MEBP bound to all of the DNA fragments (Fig. 3B) , indicating that all three subfragments contained the cis element.
All subfragments contained the sequence 5Ј-CTGGGTC-GC-3Ј (Fig. 3A) , which suggested that this nanomer is involved in protein binding. When this 9-bp sequence was tested, the band-shift assay showed that this fragment alone was sufficient for protein binding (Fig. 4, lane 3) . Band-shift assays using the 9-bp oligonucleotide with either 1-or 2-bp deletions from its 5Ј or 3Ј ends demonstrated that none of these truncated oligonucleotides interacted with MEBP (Fig. 4, lanes 4-7) . Therefore, the 9-bp sequence is the minimal MGMT DNA enhancer cis element required for efficient MEBP binding.
Characterization of MEBP-Enhancer Binding Interaction. The specificity of MEBP-DNA binding was determined by using the band-shift assay. Unlabeled 16-, 34-, and 35-bp enhancer fragments, as shown in Fig. 3A , were tested for their ability to compete with the 32 P-labeled 16-bp probe for MEBP binding. Incubation of CEM nuclear extract with 50-and 100-fold excess (125 and 250 nM) unlabeled specific competitors followed by addition of the radiolabeled 16-bp fragment resulted in a concentration-dependent reduction in complex formation (Fig. 5A ). Addition of up to 100-fold excess of a nonspecific competitor (the 22-mer SP1 binding sequence 5Ј-ATTCGATCGGGGCGGGG-CGAGC-3Ј) had no effect on complex formation (Fig. 5A ). In addition, up to 160-fold excess of a synthetic 16-mer (pBR-16bp) with the same base composition but a different sequence (5Ј-CCGGGAGCACACAAGC-3Ј) failed to compete with the specific radiolabeled probe (Fig. 5A) .
The specificity of the cis-trans interaction was examined further with the 9-bp and truncated sequences shown in Fig. 4 . The results revealed that, with the exception of cis9 (the minimum enhancer cis element), all the oligonucleotides with 1-or 2-bp deletions were ineffective competitors (Fig. 5B) .
MEBP-DNA binding characteristics were further examined by pretreating the radiolabeled 16-bp probe with DNase I and pretreating the nuclear extract with either SDS or proteinase K. All three treatments abolished the band shifts, which indicates that the complex detected in this assay is indeed composed of DNA and protein (data not shown). Southwestern blot analysis of MEBP in CEM cells indicated a single band corresponding to a protein with a molecular mass of approximately 45 kDa (Fig. 6 ). This band was completely suppressed by competition with 150-fold of the unlabeled 16-bp oligonucleotide and was not evident when probed with the random sequence pBR-16bp (Fig. 6, lanes 2 and 3) , indicating the specificity of the observed interaction in Fig. 6 , lane 1.
We also examined other Mer ϩ cell lines, including Molt 4, A204, HeLa CCL2 and Hep G2, for MEBP in their nuclei by band-shift assay. We found that MEBP was expressed in every line we examined (data not shown). 
The Cis-Trans Interaction at the 16-bp Sequence UpRegulates CAT Expression in Mer
؉ and Mer ؊ Cells. To investigate the function of the 16-bp cis element in gene expression in vivo, we transiently transfected A204 cells (a Mer ϩ cell line) with hybrid MGMT-CAT plasmid constructs (Fig. 1 ) that contained the 88-bp minimum MGMT promoter sequence plus different lengths of the enhancer fragment. Fig.  7 shows the CAT activity of these constructs relative to that of the enhancer-deficient construct, pCAT͞MP (Fig. 1, construct  I) . Relative CAT activity was significantly increased in cells transfected with enhancer-containing constructs (Fig. 1, constructs II, IV, and V) . The highest activity occurred in cells transfected with pCAT͞MP-E59, which contains the fulllength enhancer sequence (construct II). The construct pCAT͞MP-E16 (construct IV), containing the 16-bp enhancer sequence, expressed less enhancer activity than the 59-bp enhancer-containing construct, pCAT͞MP-E59 (construct II), suggesting that the sequences flanking the 16 bp are required for efficient MEBP binding and may contain additional protein-binding sites that result in high enhancer activity. Interestingly, two copies of the 16-bp enhancer sequence (construct V) produced no more CAT activity than one copy of the enhancer element (construct IV). This result indicates that a single copy of the cis element, as occurs in the natural sequence, is sufficient for enhancer activity.
When we transfected the Mer Ϫ cell line TK6 with pCAT͞ MP-E59 (construct II), CAT activity was significantly increased, relative to that of the enhancerless construct pCAT͞MP (construct I), consistent with the previous report by Harris et al. (15) . pCAT͞MP-E59inv, in which the 59-bp sequence is in the inverse orientation, also stimulated CAT expression, consistent with an enhancer function (Fig. 7) . These results indicate that the cis-trans interaction upregulates CAT expression in both Mer Ϫ and Mer ϩ cells. Subcellular Localization of MEBP. Because we found cis-trans MGMT enhancer activity in Mer Ϫ cells (Fig. 7) , we expected to find MEBP in band-shift assays with Mer Ϫ cell nuclear extracts. However, we were surprised to find that this was not the case and that MEBP was absent from Mer Ϫ nuclei. Because CAT vectors must traverse the cytoplasm, we postulated that the MEBP might be present in the cytoplasm of Mer Ϫ cells. To test this hypothesis, four Mer Ϫ ͞Mer ϩ cell pairs were selected and their Mer phenotypes were confirmed by Western blot analysis (Fig. 8) . As expected, Raji, HeLa-CCL2, HT29, and IMR90 cells were MGMT-positive (Mer ϩ ), and TK6, HeLa-S3, BE, and IMR90-890 were MGMT-deficient (Mer Ϫ ). Band-shift assays with the 16-bp enhancer fragment and nuclear or cytoplasmic extracts from these cell lines showed that MEBP was present in the nuclear extracts of all Mer ϩ cells tested, but it was completely absent from the nuclear extracts of the Mer Ϫ cells (Fig. 9) . As predicted, MEBP was present in the cytoplasm of all of the cell lines regardless of their Mer phenotype (Fig. 9) .
DISCUSSION
To understand how MGMT levels are regulated, we must begin by identifying the critical regulatory elements in the MGMT gene and the proteins that bind to those elements. The high correlation between enhancer activity and MGMT levels in Mer ϩ cells as demonstrated by CAT reporter gene assay (Fig. 2 ) strongly suggests that the 59-bp sequence at the first exon-intron boundary of the MGMT gene plays a role in regulating MGMT expression in human cells in vivo. From binding experiments using electrophoretic band-shift analysis, we learned that the minimal cis element is the 9-mer 5Ј-CTGGGTCGC-3Ј (sequence positions ϩ169 to ϩ178), and from Southwestern blot analysis, we learned that the nuclear protein that binds to this sequence is approximately 45 kDa.
A search of the known transcription factor binding motifs, using the program SIGNAL SCAN (27) , identified a single sequence in an SV40 enhancer element that showed a 7-base homology with the MGMT 9-mer. No binding protein has yet been identified for the SV40 enhancer element (28) . Although the minimal protein binding element for the MGMT gene is only a 9-mer, enhancer activity in CAT assays increased as we extended the length of the element (Fig. 7) , suggesting that the 5Ј and 3Ј flanking sequences of this enhancer contribute to efficient transcriptional activity.
The most surprising aspect of these studies was the finding that the 59-bp enhancer functioned effectively in CAT assays in Mer Ϫ cells, yet the MEBP was absent from Mer Ϫ nuclei. This apparent contradiction was resolved with the finding that MEBP is in fact present in the cytoplasm of Mer Ϫ cells (Fig. 9) . The 59-bp element is a very strong enhancer-its deletion from the maximal MGMT promoter results in greater than 95% loss of promoter activity in CAT assays (14) . It is possible, therefore, that the exclusion of MEBP from the nucleus of Mer Ϫ cells accounts for the drastic down-regulation of MGMT in these cells.
Transcription of MGMT in Mer Ϫ cells has been undetectable (9) (10) (11) 29) in all but one study, which used extensive reverse transcription-coupled PCR (30) . If the residual promoter activity observed in CAT assays in the absence of the 59-bp enhancer occurs in vivo, then additional mechanisms must be involved to account for the total suppression of the MGMT gene in Mer Ϫ cells.
Sequestration of a transcription factor in the cytoplasm is not without precedent as a mechanism for transcriptional suppression. Loss of p53 function has been attributed to its abnormal cytoplasmic sequestration with concomitant nuclear exclusion (31) . There are numerous potential mechanisms for the nuclear exclusion of MEBP. Mutation in a putative nuclear targeting domain of MEBP is one possibility, which could be addressed by the isolation of the MEBP cDNA-a goal we are actively pursuing. Alternatively, Mer Ϫ cells may have alterations in their nuclear membranes that impede MEBP translocation; MEBP may be abnormally anchored to a cytoplasmic structure or protein, or the MEBP of Mer Ϫ cells may be unable to bind to a nuclear target. It is also possible that biochemical modification, such as phosphorylation, may be required for MEBP to translocate into the nucleus and that such modification is altered in Mer Ϫ cells.
To date, the only clear difference between Mer ϩ and Mer Ϫ cells, apart from MGMT suppresion, relates to cytosine methylation of the gene (32) . Specifically, the CpG island at the 5Ј flanking region of the gene, which includes the promoter and the 59-bp enhancer region, is highly methylated in Mer Ϫ cells, whereas it is totally methylation free in Mer ϩ cells (33, 34) . The role of such methylation in gene suppresion is still a matter of controversy (35) ; both views, one that methylation directly affects transcription factor binding and the other that failure of transactivating proteins to bind permits methylation, may prevail. It seems unlikely that nuclear localization of the MEBP is due to its tight binding to the enhancer element and that its nuclear exclusion is a result of methylation at the enhancer site. It seems more likely that when MEBP is excluded from the nucleus and MGMT transcription is down-regulated, the associated conformational change in the cis-enhancer element could expose it to DNA methylase, leading to de novo CpG methylation and stabilization of the transcriptional status (35) . In summary, we have observed a difference between the intracellular distribution of MEBP in Mer ϩ and Mer Ϫ cells that suggests MEBP not only plays a role in the regulation of constitutive MGMT expression in Mer ϩ cells but may also account for MGMT down-regulation in Mer Ϫ cells. Isolation of the MEBP gene from both Mer ϩ and Mer Ϫ cells and characterization of the encoded protein should help define the mechanism for MEBP nuclear exclusion and provide further insights into MGMT regulation in both normal and malignant cells.
